Janumet mg/500 mg Tablet is a combination medication used to manage high blood sugar levels in patients with type 2 diabetes. This treatment helps prevent serious diabetes complications like kidney impairment and vision loss, while potentially reducing risks of heart attack and stroke.
Janumet mg/500 mg Tablet can be prescribed as monotherapy or alongside other antidiabetic medications. Optimal results are achieved when combined with a balanced diet and regular physical activity. Dosage is determined by your medical condition, glucose levels, and concurrent medications. Taking it with meals minimizes gastrointestinal discomfort.
For maximum effectiveness, maintain consistent daily dosing times and continue treatment unless advised otherwise by your physician. Adherence to your doctor’s recommended diet and exercise regimen is crucial during therapy, as lifestyle factors significantly impact diabetes management.
Common adverse effects may include diarrhea, nausea, vomiting, abdominal discomfort, headaches, and throat irritation. Concurrent use with insulin or sulfonylureas may increase hypoglycemia risk – patients should learn to recognize and manage low blood sugar symptoms.
This medication isn’t appropriate for all individuals. Inform your healthcare provider about any history of renal, hepatic, or cardiac conditions, pancreatic disorders, or excessive alcohol consumption. Pregnant or nursing women should seek medical advice before use. Disclose all current medications to assess potential interactions. Alcohol consumption should be minimized as it can lower blood glucose. Regular kidney function and blood sugar monitoring will be conducted throughout treatment.
THERAPEUTIC INDICATIONS
- Management of type 2 diabetes mellitus
CLINICAL BENEFITS
For Type 2 Diabetes Management
ADVERSE EFFECTS
Frequently Reported Reactions
- Gastrointestinal disturbances (diarrhea, nausea, vomiting)
- Abdominal discomfort
- Cephalalgia (headache)
- Nasal obstruction
- Pharyngeal irritation
- Upper respiratory infections
- Increased hypoglycemia risk when combined with insulin or sulfonylureas
ADMINISTRATION GUIDELINES
PHARMACOLOGICAL ACTION
Disclaimer:
Reviews
There are no reviews yet